Related references
Note: Only part of the references are listed.被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
F. Cappuzzo et al.
BRITISH JOURNAL OF CANCER (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Reflections on medical oncology: 25 years of clinical trials - Where have we come and where are we going?
Christopher M. Booth et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis
Chang Youl Lee et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
HE Jones et al.
ENDOCRINE-RELATED CANCER (2004)
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
HM Khandwala et al.
ENDOCRINE REVIEWS (2000)
Share Paper
